HolderBook

ROCKET PHARMACEUTICALS INC (RCKT)

Institutional ownership reported to the SEC as of Q3 2026, across 32 quarters.

2
Reporting holders
$9.6K
Reported value
0.0%
Calls
0.0%
Puts
-178
Holder change

Calls and puts are the parts of reported value carried in derivative lines rather than shares, and they point in opposite directions: a manager holding calls is positioned for the security, one holding puts against it - or hedging shares they already own, which is why index funds carry so many. Most sites add the two together and report one figure, which averages away the only interesting part.

Holders

Download these holders as CSV

FilerValueShares Their book Held Change
Farther Finance Advisors, LLC$6.0K2,2770.00%13q-14.2%
GAMMA Investing LLC$3.6K1,3590.00%4q+12.0%

Five percent filings

Anyone crossing 5% of a company must say so within days - far sooner than the next quarterly holdings report. A 13D declares an intent to influence the company; a 13G is the passive version. See all activist filings →

FiledFormFiler % of class
2026-07-3113GVanguard Portfolio Management5.3%

Tender offers and delisting

Schedules TO, 13E-3 and 14D-9 and Form 25 filed in the last 180 days. Price a share is read from the filing itself where it states one plainly; a marker means we found no figure we could stand behind, and the reason is on it.

FiledWhatFiled byPrice a shareSource
2026-09-02Delisting notice from the exchangeNasdaq Stock Market LLC-filing

What the company announced

Form 8-K filings from the last 120 days, showing only the items worth a reader's attention. Earnings releases, exhibit attachments and general disclosures are filed constantly and are left out. Filed is when the SEC received it; event is the date the company says the thing happened.

FiledEvent dateWhatSource
2026-10-062026-09-30Material agreement enteredfiling
2026-08-272026-08-21Directors or officers departed or appointedfiling

What the insiders did

Open market purchases and sales reported on Form 4 in the last 180 days. Grants, option exercises and shares surrendered to cover tax are left out: they are compensation rather than a decision to buy or sell. Where a broker filled one order in tranches the lines are summed, because it was one decision.

Officers and directors

DateInsiderRoleSideSharesValue
2026-09-11Wilson MartinGeneral CounselSold75,364$256.5K
2026-05-21Shah GauravCEOSold55,684$171.8K
2026-08-11Stevens Christopher JamesChief Operating OfficerSold36,658$128.3K

Quarter by quarter

Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.

QuarterHoldersValue SharesNewAdded TrimmedOptions
Q3 20262$9.6K3,6360110.0%
Q2 2026180$352.4M102,567,9651970620.5%
Q1 2026197$350.0M97,309,0964478530.5%
Q4 2025183$323.0M91,305,5322758700.0%
Q3 2025173$325.2M98,910,3142857630.9%
Q2 2025196$238.4M96,275,4503977451.0%
Q1 2025238$728.9M108,144,86148107400.6%
Q4 2024224$1.4B109,701,3094693420.3%
Q3 2024191$1.7B93,273,8493263500.3%
Q2 2024180$2.0B92,180,8411872490.2%
Q1 2024190$2.5B94,414,0112064590.4%
Q4 2023196$2.7B90,396,8623166630.6%
Q3 2023177$1.8B89,403,1523077410.9%
Q2 2023163$1.5B77,551,3911759540.1%
Q1 2023162$1.4B79,654,0161774340.2%
Q4 2022168$1.5B76,465,4073077381.2%
Q3 2022163$1.1B69,077,5943159360.9%
Q2 2022146$892.0M64,794,8512553400.0%
Q1 2022145$1.0B64,563,2132255370.0%
Q4 2021145$1.4B65,697,4851956380.0%
Q3 2021145$1.9B61,978,1931152470.1%
Q2 2021153$2.9B64,680,2571164460.4%
Q1 2021173$2.8B62,026,3192672490.4%
Q4 2020176$3.4B62,238,7915452470.8%
Q3 2020126$1.3B55,254,8042038430.0%
Q2 2020119$1.1B54,513,8852648260.1%
Q1 2020106$748.1M53,569,2681343280.1%
Q4 2019122$1.2B52,378,3163239280.1%
Q3 201993$558.2M47,913,8931439190.1%
Q2 201996$750.0M49,530,6412147150.9%
Q1 201982$761.7M43,195,8491032160.7%
Q4 201887$627.6M42,454,5592120.1%